CJC-1295 With DAC (5mg)

Technical Specifications

CJC-1295 with Drug Affinity Complex (DAC) is a 30-amino acid synthetic analog of human growth hormone-releasing hormone (GHRH) engineered for markedly extended plasma persistence. Developed by ConjuChem Biotechnologies in 2005, the compound incorporates four strategic amino acid substitutions to resist enzymatic degradation and a C-terminal maleimidopropionyl-lysine moiety that forms a covalent thioether bond with serum albumin Cys-34, extending the biological half-life from approximately 30 minutes to 5.8-8.1 days.

Clinical investigation has generated a significant body of peer-reviewed literature. Pivotal human trials published in the Journal of Clinical Endocrinology & Metabolism demonstrated sustained, dose-dependent increases in GH concentrations of 2- to 10-fold for six or more days, and IGF-1 elevations of 1.5- to 3-fold persisting 9-11 days after a single injection. CJC-1295 DAC advanced to Phase II clinical trials for HIV-associated lipodystrophy before the program was terminated in 2006.

Key Research Highlights

Research Applications

• GHRH receptor signaling and G-protein coupled receptor biology
• Growth hormone/IGF-1 axis pharmacology
• Pituitary somatotroph cell biology
• Long-acting peptide drug design and albumin-binding technology
• Metabolic research and body composition studies
• Anti-doping analytical chemistry method development